Assessing effects of treatment with lisdexamfetamine dimesylate for pediatric ADHD using a parental survey

CNS Spectrums

Volumn 15, Issue 4, 2010, Pages 248-256

  Antonucci, Donna ^a   Kunins, Craig ^b   Manos, Michael ^c   López, Frank A ^d   Kerney, Donna L ^e  

^a and Behavior ^*

^b Center for Pediatric Behavioral Health   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d Children's Developmental Center   (United States)

^e Children's Developmental Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; LISDEXAMFETAMINE;

ACADEMIC ACHIEVEMENT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG DOSE REGIMEN; FAMILY INTERACTION; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; PARENTAL BEHAVIOR; PATIENT COMPLIANCE; PRIORITY JOURNAL; SATISFACTION; SOCIAL INTERACTION; SYMPTOM; TREATMENT DURATION;

EID: 77952568797     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900000080     Document Type: Article

References (15)

1. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet. 2005;366:237-248.
2. Vyvanse [package insert]. Wayne, PA: Shire US Inc; 2008.
3. Biederman J, Boellner SW, Childress A, López FA, Krishnan S, Zhang Y. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry. 2007;62:970-976.
4. Ermer J, Homolka R, Martin P, Buckwalter M, Purkayastha J, Roesch BG. Linear dose proportionality, low inter and intra subject variability, and safety of lisdexamfetamine dimesylate in an open-label single-dose pharmacokinetic study in healthy adult volunteers. Poster presented at: U.S. Psychiatric and Mental Health Congress; October 30-November 2, 2008; San Diego, CA.
5. Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007;29:450-463.
6. Wigal SB, Kollins SH, Squires LA, Childress AC. Lisdexamfetamine dimesylate demonstrated efficacy throughout the day up to 13 hours in an analog classroom study in children with attention-deficit/hyperactivity disorder. Poster presented at: American Academy of Child & Adolescent Psychiatry Annual Meeting; Oct 28-Nov 2, 2008; Chicago, IL.
7. López FA. ADHD: new pharmacological treatments on the horizon. J Dev Behav Pediatr. 2006;27:410-416.
8. Findling R, Jain R, Gao J, Richards C, Ginsberg L. A dose-optimization study of the efficacy, safety, and tolerability of lisdexamfetamine dimesylate in children aged 6 to 12 years with attention-deficit/hyperactivity disorder. Poster presented at: American Academy of Child & Adolescent Psychiatry Annual Meeting; Oct 28-Nov 2, 2008; Chicago, IL.
9. Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ. 2001;165:1475-1488.
10. Faraone SV, Biederman J, Roe C. Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis. J Clin Psychopharmacol. 2002;22:468-473.
11. Biederman J, Faraone SV, Monuteaux MC, Grossbard JR. How informative are parent reports of attention-deficit/hyperactivity disorder symptoms for assessing outcome in clinical trials of long-acting treatments? A pooled analysis of parents' and teachers' reports. Pediatrics. 2004;113:1667-1671.
12. Biederman J, Gao H, Rogers AK, Spencer TJ. Comparison of parent and teacher reports of attention-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children. Biol Psychiatry. 2006;60:1106-1110.
13. Sallee FR, Ambrosini PJ, López FA, Shi L, Michaels MA; LADD.CAT Study Group. Health-related quality of life and treatment satisfaction and preference in a community assessment study of extended-release mixed amphetamine salts for children with attention-deficit/hyperactivity disorder. J Outcomes Res. 2004;8:27-49.
14. Trattler W, Katsev D, Kerney D. Self-reported compliance with topical cyclosporine emulsion 0.05% and onset of the effects of increased tear production as assessed through patient surveys. Clin Ther. 2006;28:1848-1856.
15. Kerney DL, Paradis D, Brunton S. Patient perceptions of insulin detemir as reported through patient telephone surveys. Curr Med Res Opin. 2007;23:2043-2049.